title: [Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis C: two case reports].
authors.forename: Beatriz
authors.initials: B
authors.lastname: Guglieri-López
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Ventura-Cerdá
authors.forename: Jorge
authors.initials: J
authors.lastname: Carmena-Carmena
authors.forename: Mónica
authors.initials: M
authors.lastname: Climente-Mónica
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D013926:Thrombopoietin / Q000172:deficiency
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents; D001565:Benzoates; D006834:Hydrazines; D016898:Interferon-alpha; D009842:Oligopeptides; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins; C082218:MPL protein, human; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; D013926:Thrombopoietin; C100416:peginterferon alfa-2a; C520809:eltrombopag